Biocon Biologics Expands Strategic Collaboration with Civica to Increase Access to Affordable Insulins in the United States

Strategic Insights -

Biocon Biologics Ltd., a leading global biosimilars company, has announced an expansion of its strategic collaboration with Civica, Inc. to include a new Insulin Glargine medicine. This multi-year agreement aims to increase the supply of high-quality, affordable insulins in the United States, benefiting patients with diabetes. The agreement establishes an exclusive distributorship arrangement between Biocon Biologics and Civica, where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, which will commercialize and distribute it in the United States under a separate Civica label and trade dress. This collaboration enables Biocon Biologics to reach underserved populations through new channels, aligning with its mission to expand access to affordable, high-quality insulins.

Key Takeaways:

  • Biocon Biologics has expanded its strategic collaboration with Civica, Inc. to include a new Insulin Glargine medicine, increasing the supply of high-quality, affordable insulins in the United States.
  • The agreement establishes an exclusive distributorship arrangement between Biocon Biologics and Civica, where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica.
  • Civica will commercialize and distribute the medicine in the United States under a separate Civica label and trade dress.
  • The agreement expands the relationship between Biocon Biologics and Civica, which previously announced a partnership for Insulin Aspart drug substance manufacture in the United States.
  • Biocon Biologics will continue to directly commercialize its own Insulin Glargine-yfgn medicine, approved by the FDA in July 2021 as the first interchangeable biosimilar.
  • Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., stated that this collaboration enables the company to reach underserved populations through new channels in direct alignment with its mission.
  • Ned McCoy, President and Chief Executive Officer, Civica, Inc., said that this expansion helps achieve a significant milestone in their insulin initiative and brings insulin to people who need it at a transparent low price.
  • Insulin glargine-yfgn injection is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
  • There are 38.4 million people with diabetes in the United States, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed.

Statistics:

  • Biocon Biologics provides over 9.2 billion doses of insulin globally with a broad portfolio comprising basal, mixed, and rapid-acting insulins.
  • An additional 97.6 million Americans have been identified as prediabetic.
  • 38.4 million people have diabetes in the United States, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed.

Sources:

  • Biocon Biologics Ltd. press release, November 1, 2025.
  • Biocon Biologics Ltd. (BSE code: 532523, NSE: BIOCON)
  • U.S. Food and Drug Administration (FDA)
  • Civica, Inc.
  • NewsRx LLC.